- Home
- EDD vs SLP Comparison
EDD vs SLP Comparison
Compare EDD & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- SLP
- Stock Information
- Founded
- EDD 2007
- SLP 1996
- Country
- EDD United States
- SLP United States
- Employees
- EDD N/A
- SLP N/A
- Industry
- EDD Finance Companies
- SLP EDP Services
- Sector
- EDD Finance
- SLP Technology
- Exchange
- EDD Nasdaq
- SLP Nasdaq
- Market Cap
- EDD 345.5M
- SLP 322.4M
- IPO Year
- EDD N/A
- SLP 1997
- Fundamental
- Price
- EDD $5.35
- SLP $17.38
- Analyst Decision
- EDD
- SLP Buy
- Analyst Count
- EDD 0
- SLP 8
- Target Price
- EDD N/A
- SLP $26.80
- AVG Volume (30 Days)
- EDD 254.3K
- SLP 418.1K
- Earning Date
- EDD 01-01-0001
- SLP 12-01-2025
- Dividend Yield
- EDD 7.52%
- SLP N/A
- EPS Growth
- EDD N/A
- SLP N/A
- EPS
- EDD N/A
- SLP N/A
- Revenue
- EDD N/A
- SLP $80,383,000.00
- Revenue This Year
- EDD N/A
- SLP $13.67
- Revenue Next Year
- EDD N/A
- SLP $1.50
- P/E Ratio
- EDD N/A
- SLP N/A
- Revenue Growth
- EDD N/A
- SLP 20.01
- 52 Week Low
- EDD $4.22
- SLP $12.39
- 52 Week High
- EDD $4.95
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- EDD 51.83
- SLP 54.59
- Support Level
- EDD $5.32
- SLP $16.97
- Resistance Level
- EDD $5.38
- SLP $17.80
- Average True Range (ATR)
- EDD 0.05
- SLP 0.76
- MACD
- EDD 0.01
- SLP -0.09
- Stochastic Oscillator
- EDD 52.82
- SLP 35.04
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.